Uterine Fibroids Treatment Market- Growth, Trends, Covid-19 Impact, And Forecasts (2022 - 2027)

The Uterine Fibroids Treatment Market is Segmented by Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), Treatment (Drugs (Progesterone, Levonorgestrel, and Others), Surgical Techniques (Hysterectomy, Myomectomy, Myolysis, Others)), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (USD million) for the above segments.

Market Snapshot

Uterine Fibroids Treatment Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 4.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Uterine Fibroids Treatment Market is projected to register a CAGR of 4.5% during the forecast period (2022-2027).

The coronavirus pandemic has caused major changes worldwide, especially in healthcare systems. The COVID-19 pandemic resulted in the cancellation of all elective procedures. While patients with uterine fibroids are not at risk in the same way as Critical Limb Ischemia patients are, their quality of life has been adversely impaired in some cases. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments. As a result, restrictions on access to elective therapies, imposed either to decrease virus cross-transmission or to prepare the hospital structure to aid infected patients, have forced women to live with discomfort and ineffective temporary treatments.

The market is likely to be driven by the high prevalence of uterine fibroids among women worldwide, increased patient preference for less invasive procedures, and the adoption of technologically sophisticated technologies. Excessive menstrual flow, pelvic pain, infertility, and frequent urination are all symptoms of uterine fibroid (UF), a benign tumor of the smooth muscle cells that grow in the uterus. Even though the etiology is unknown, race, age, genetic susceptibility, premenopausal status, hypertension, overweight, and diet are all risk factors. Per the article published by Contemporary OB/GYN in February 2022 on "A Look At the Current State of Uterine Fibroid Care," over 70% of women are estimated to develop uterine fibroids by age 50.

Furthermore, the market is predicted to develop due to patients' preference for minimally invasive and non-invasive fibroids operations. Smaller incisions reduce post-operative pain and speed recovery, resulting in the widespread use of these procedures. Several major firms are investing in R&D to bring new minimally invasive and non-invasive surgical devices to market. One of the incision-less techniques physicians commonly suggest is MR-guided Focused Ultrasound (MRgFUS) for treating uterine fibroids. The gadget emits ultrasonic beams, which heat and remove specific tissue from the uterine cavity during this treatment. As this is a non-invasive procedure, there are little to no side effects, and patients can resume normal activities within a few days. As a result of the increased demand for such operations due to their little pain, efficacy, low risk of infection, and quick recovery compared to open surgeries, the market for uterine fibroids treatment devices is expected to rise.

Expanding uterine fibroids awareness and education beyond gynecologic professionals and promoting individualized patient treatment through collaborative decision-making were also flagged as ways to address unmet needs. For example, in November 2021, Minerva Surgical, Inc. (a women's health company specializing in treating AUB) announced the introduction of www.aubandme.com, a new consumer education experience for women. Furthermore, investigating novel non-hormonal medical therapy could lead to advanced fibroids treatment options that do not affect fertility. Upregulation of vitamin D, for example, could protect against fibroid growth while having no harmful influence on ovarian function. Furthermore, Bayer invests in uterine fibroids as part of its clinical development program.

Hence, the availability of advanced products, surgical techniques, and initiatives by various market players contribute to the overall market growth.

Scope of the Report

As per the scope of this report, uterine fibroids, also known as uterine myomas or leiomyomas, are non-cancerous tumors that develop in the muscular wall of the uterus. They can vary in size and number. Symptoms include heavy menstrual bleeding (HMB), anemia, abdominal pressure and pain, bloating, increased urinary frequency, and reproductive dysfunction. The Uterine Fibroids Treatment Market is Segmented by Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids), Treatment (Drugs (Progesterone, Levonorgestrel, and Others), Surgical Techniques (Hysterectomy, Myomectomy, Myolysis, Others)), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Type
Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids
By Treatment
Surgical Techniques
By End-user
Ambulatory Surgical Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Hysterectomy Segment is Expected to Hold a Major Market Share in the Uterine Fibroids Treatment Market

The worldwide impact of COVID-19 continues to be felt as hospitals in all countries reduce elective and non-urgent cases to allow staffing and resources to be deployed elsewhere. As per the article published in 2021 on “Gynecological Laparoscopic Surgeries in the Era of COVID-19 Pandemic: A Prospective Study”, A joint statement issued by the American Association of Gynecologic Laparoscopists (AAGL), American College of Obstetricians & Gynaecologists (ACOG), and other organizations advised the suspension of elective surgery, shifting the focus to emergency and cancer surgery.

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the category will likely grow as the number of related surgeries increases. As per the article published in November 2020 on “Hysterectomy in the United States", by Verywell Health, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United States each year. According to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

For severe menstrual bleeding, ablation procedures are a frequent surgical treatment. The endometrial lining of the uterus is surgically abated in this minimally invasive procedure. Endometrial ablation requires no incisions and can be performed in the doctor’s office without general anesthesia. Furthermore, after the endometrial ablation operation, pregnancy is conceivable. As a result, the advantages afforded by ablation procedures are projected to propel the segment forward.


North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

The pandemic of COVID-19 has a significant impact on gynecologic surgery. The American College of Surgeons suggested delaying all non-essential invasive surgeries in March 2020. According to a December 2021 study article titled "Analysis of COVID-19 Response and Impact on Gynecologic Surgery at a Large Academic Hospital System," 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. The most common procedure in 2020 was a hysterectomy, whereas surgery for endometriosis and uterine fibroids saw the greatest decline in volume. Many patients had significant delays in receiving gynecologic surgical care during the peak pandemic.

The presence of well-established healthcare facilities in the region increased government initiatives, and an increase in hysterectomy-related surgical procedures/hospital visits are all driving the market in North America. Furthermore, the presence of major important companies like Medtronic, Stryker, and CooperSurgical, Inc. and the availability of technologically improved goods all contribute to the region's market growth. Furthermore, the region's adoption of uterine fibroids treatment devices is fueled by the region's easy access to healthcare technologies and strong distribution channels.

Various governments and commercial groups are working to raise awareness of early fibroids detection and treatment through various efforts. In the United States, for example, July is designated as "Fibroids Awareness Month." In recent years, more initiatives have raised awareness about uterine fibroids. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are just a few famous programs. The White Dress Project aims to raise awareness about fibroids by generating funding for research and educating women on the basics. This initiative encourages and supports women to join and share their stories. In addition, the Fibroids Project is an online community and website dedicated to assisting women in becoming fibroids-free. They aim to provide information about current research, initiatives, and procedures to both women and medical professionals. Growing awareness among women about uterine fibroids treatment and activities is expected to promote market growth.

Uterine Fibroids Treatment Market Analysis

Competitive Landscape

The uterine fibroids treatment market is fragmented and competitive and consists of several major players. Some players operating in the market are Myovant Sciences GmbH; Gynesonics, Boston Scientific Corporation, INSIGHTEC, Hologic, Inc., Karl Storz Gmbh, Minerva Surgical, Inc., Pfizer, Inc., Abbvie, Inc., and ObsEva. Market players are adopting various strategies such as mergers, acquisitions, and new product developments to remain competitive.

Recent Developments

  • In May 2021, Myovant Sciences and Pfizer Inc. announced that the United States Food and Drug Administration (FDA) had approved MYFEMBREE, the first once-daily treatment for managing heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months.
  • In February 2021, Pfizer and Myovant released favorable results from the Phase III LIBERTY 1 and LIBERTY 2 investigations. In women with uterine fibroids, the companies are testing a once-daily combination therapy of relugolix plus estradiol and norethindrone acetate.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Technological Advancements

      2. 4.2.2 Growing Prevalence of Uterine Fibroids

    3. 4.3 Market Restraints

      1. 4.3.1 Complications Associated with Morcellators

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Subserosal Fibroids

      2. 5.1.2 Intramural Fibroids

      3. 5.1.3 Submucosal Fibroids

      4. 5.1.4 Pedunculated Fibroids

    2. 5.2 By Treatment

      1. 5.2.1 Drugs

        1. Progesterone

        2. Levonorgestrel

        3. Others

      2. 5.2.2 Surgical Techniques

        1. Hysterectomy

        2. Myomectomy

        3. Myolysis

        4. Others

    3. 5.3 By End-user

      1. 5.3.1 Hospitals

      2. 5.3.2 Ambulatory Surgical Centers

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Myovant Sciences GmbH

      2. 6.1.2 Gynesonics

      3. 6.1.3 Medtronic

      4. 6.1.4 Boston Scientific Corporation

      5. 6.1.5 INSIGHTEC

      6. 6.1.6 Hologic, Inc.

      7. 6.1.7 Karl Storz Gmbh

      8. 6.1.8 Minerva Surgical, Inc.

      9. 6.1.9 Pfizer, Inc.

      10. 6.1.10 Abbvie, Inc.

      11. 6.1.11 ObsEva

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Uterine Fibroids Treatment Market market is studied from 2019 - 2027.

The Global Uterine Fibroids Treatment Market is growing at a CAGR of 4.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Gynesonics, Medtronic, INSIGHTEC, Myovant Sciences GmbH, Boston Scientific Corporation are the major companies operating in Global Uterine Fibroids Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!